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ABSTRAK 
 
Pengenalan 
 
HbE/ talasemia beta merupakan salah satu daripada hemoglobinopati yang biasa ditemui di Asia 
Tenggara dan kini telah menjadi satu masalah kesihatan awam yang kritikal. Selain daripada 
anemia patologikal, ia juga mempunyai ciri-ciri utama lain seperti hepatosplenomegali dan 
deformasi struktur rangka tulang kraniofasial. Biometri okular juga turut terjejas akibat kelainan 
pada tumbesaran rangka tulang orbit. Selain itu juga, terdapat ciri-ciri lain seperti perubahan pada 
struktur saraf retina dan optik yang berlaku pada pesakit ini. 
 
Objektif 
 
Membandingkan purata ketebalan makula, ketebalan serat saraf retina dan parameter kepala saraf 
optik antara kumpulan pesakit HbE/ talasemia beta dengan kumpulan kawalan. 
 
Metodologi 
 
Satu kajian rentas telah dijalankan di Hospital Universiti Sains Malaysia bermula dari bulan Jun 
tahun 2014 sehingga bulan Mac 2016. Pesakit yang telah disahkan dengan HbE/ talasemia beta 
dan populasi yang normal dan sihat telah dipilih berdasarkan ciri-ciri inklusi dan eksklusi kajian. 
Data ketebalan makula, ketebalan serat saraf retina dan parameter kepala saraf optik telah diukur 
xv 
 
menggunakan Cirrus HD-OCT. Analisa statistik telah dilakukan dengan menggunakan perisian 
SPSS versi 22.0 
 
Keputusan 
 
Sejumlah 132 peserta telah terlibat dalam kajian ini (66 pesakit HbE/ talasemia beta dan 66 subjek 
kawalan). Tiada perbezaan yang signifikan dalam purata ketebalan makula bagi kedua-dua 
kumpulan. Tiada perbezaan signifikan pada purata ketebalan serat saraf retina. bagi kumpulan 
HbE/ talasemia dan kumpulan kawalan. Tiada perbezaan yang signifikan turut didapati untuk 
parameter kepala saraf optic bagi kedua-dua kumpulan.  
 
Kesimpulan 
 
Kajian ini telah menunjukkan tiada perbezaan signifikan pada purata ketebalan macula, purata 
ketebalan serat saraf retina dan parameter kepala saraf optic bagi kumpulan HbE/ talasemia dan 
populasi yang normal. 
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ABSTRACT 
   
Introduction 
 
HbE/ β-thalassemia is one of the hemoglobinopathy that commonly found in South East Asia 
(SEA) and it has become a severe public health problem today. Apart from the pathological 
anemia, they also share other common features like hepatosplenomegaly and craniofacial bony 
deformities. Ocular biometry can be affected as well due to abnormal growth of the orbital bone. 
Other than these, structure of the retina and the optic nerve may be altered in these patients. 
 
Objective 
 
To compare mean macular thickness, retinal nerve fiber layer (RNFL) thickness and optic nerve 
head (ONH) parameters between HbE/ β-thalassemia group and control. 
 
Methods 
 
This is a cross-sectional study conducted in Hospital Universiti Sains Malaysia from June 2014 
till March 2016. Patients with confirmed HbE/ β-thalassemia and healthy population were selected 
based on the inclusion and exclusion criteria. Baseline macular thickness, RNFL thickness and 
ONH parameters were measured by using Cirrus HD-OCT. Statistical analysis was performed 
using SPSS version 22.0. 
 
xvii 
 
Results 
 
A total of 132 participants were recruited (66 participants in HbE/ β-thalassemia group and 66 
participants in control). There was no significant difference in mean macular thickness in between 
the two groups. No significant different found in the mean RNFL thickness in between HbE/ β-
thalassemia and control. There was also no significant difference in ONH parameters between two 
groups.  
 
Conclusion 
 
The study revealed that there was no significant differences in both mean macular thickness, RNFL 
thickness and ONH parameters in between HbE/ β-thalassemia and normal population. 
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Chapter 1  
 Introduction 
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1.1 THALASSEMIA 
 
Thalassemia was derived from 2 Greek words; Thalassa (sea) and Anemia. In the early 20th 
century, most of the cases were reported in children of Mediterranean origin, therefore 
Thalassa alluded to the Mediterranean Sea (Whipple and Bradford, 1936). Thalassemia, in 
other words, is also known as Mediterranean anemia. It is an autosomal recessive inherited 
hemoglobin disorder. According to evidences in research, HbA and HbF consist of 2 α chains 
which are combined with a β, delta or gamma chains (Cao and Galanello, 2010). As reported 
by Weatherall (1998), hemoglobinopathies are disorders which can be traced to mutations 
within specific globin genes including α or β which can cause ineffective erythropoiesis. 
Based on the types of globin defects, the thalassemia can be divided into α and β. Alpha-
thalassemia occurs when a gene or genes related to the α-globin proteins are missing or 
mutated. Whereas, β-thalassemia occurs if a gene or genes related to the β-globin proteins are 
involved and result in deficiency of β-globin chain synthesis (Thein, 2005).  
 
1.2 HEMOGLOBIN E 
 
HbE is an abnormal β-hemoglobin variant. This HbE allele structural variant has a substituted 
amino acid at position 26, from glutamic acid to lysine (Olivieri et al, 2011), which results in 
a structurally abnormal hemoglobin molecule, further resulting in abnormal processing of 
mRNA (Orkin et al, 1982). This mRNA is non-functional as a result of an associated 
generation of a new-stop codon (Datta et al, 2006). Evidences in research further concluded 
that such abnormal processing can result in multiple pathophysiological conditions which are 
aimed at reducing the β chain synthesis. This can result in limited erythropoiesis as well as 
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associated with the shortening of red cell survival (Pootrakul et al, 2000). Hence, individuals 
with HbE are characterized with a mild form of β-thalassemia (Olivieri et al, 2011). 
  
1.2.1 Epidemiology of Hemoglobin E 
 
HbE populations are commonly found in SEA especially in Cambodia, Thailand and Laos, 
where the prevalence can range from 25% to 60%; the distribution of HbE in Malaysia ranges 
from 4% to 45% of the population (Weatherall and Clegg, 2001; Fucharoen and Winichagoon, 
1997). Due to the population migration, they can also be found in the countries other than 
SEA, such as Bangladesh, Sri Lanka and Nepal (Weatherall and Clegg, 2001; Fucharoen and 
Winichagoon, 1997). The carrier rate of HbE in SEA is high especially in Cambodia, Laos, 
and Thailand, which ranges from 4% to 80%; in Malaysia, it has been estimated as 3% to 40% 
(Weatherall and Clegg, 2001).  
 
1.3 HEMOGLOBIN E/ BETA THALASSEMIA 
 
This disorder is found to occur as a result of the co-inheritance of the β-thalassemia allele 
from one parent and the HbE structural variant from the other parent (Agarwal et al, 1997). 
Extant literatures have reported that HbE/ β-thalassemia is represented by 50% of all 
individuals who have been affected by severe thalassemia (Fucharoen and Winichagoon, 
1997; Modell and Darlison, 2008). The presence of this disorder is more common in SEA 
including Cambodia and Thailand where individuals inherit the allele for HbE and β-
thalassemia (Weatherall and Clegg, 2001). In Malaysia, George (2013) added the Malays and 
Orang Asli populations are the 2 most common groups in peninsular Malaysia that suffer 
from HbE/ β-thalassemia. Based on a cohort study by Hanafi et al, (2014), HbE/ β-
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thalassemia can be classified phenotypically into HbE/b0 and HbE/b+, where b0 is without a β-
globin chain synthesis; b+ with some degree of β-globin chain synthesis. Clinically, the 
severity of the HbE/ β-thalassemia can be grouped into mild, moderate and severe based on a 
new scoring system (Sripichai et al, 2008). The scores (0-10) are obtained based on few 
parameters including age of presenting illness, age of receiving the ﬁrst transfusion, 
frequency of transfusion, level of the hemoglobin, spleen size, and the status of growth and 
development in HbE/ β-thalassemia patients (Sripichai et al, 2008). With the assistance of 
this new classification system, Sripichai et al, (2008) found that the HbE/ β-thalassemia 
patients were almost equally distributed into 3 groups with different severity. 
 
1.3.1 Clinical Features of HbE/ β-Thalassemia 
 
According to Weatherall (2000), the clinical features of HbE/ β-thalassemia can range from 
minor to major. As Fucharoen and Winichagoon (2000) reported those individuals who are 
most severely affected are transfusion dependent and show signs of intermittent jaundice, 
possible retardation of growth, expansion of the bone marrow cavity and more importantly 
hepatospenomegaly. Another common feature in severe β-thalassemia is craniofacial bony 
deformities which comprises of bossing of the skull, depression of the nasal bridge, 
prominent malar eminence, hypertrophy of the maxillae and mongoloid slant of the eye. 
However, Olivieri et al (2008) reported that those individuals who are less severely affected 
and not on regular transfusion are also found to exhibit many of these symptoms. Although 
the pathogenesis of bone changes is not completely understood, it is believed to relate with an 
abnormal turnover in bone mineral resulting from increased resorption and suppression of 
osteoblast activity (Morabito et al, 2004). Besides, more than 20% of the HbE/ β-thalassemia 
patients were reported to have respiratory tract infections; about 10% of them had 
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complications with CHF and some may get chronic leg ulcer, bone pain, septicemia and even 
transfusion related CNS complication such as cerebral haemorrhage (Fucharoen et al, 2000). 
The death is either caused by the disease or treatment related complications. It was reported 
that CHF and septicemia were the main cause of death, and about 65% of the HbE/ β-
thalassemia patients die in the 3rd to 4th decade of their life (Fucharoen et al, 2000). 
 
1.3.2 Treatment of HbE/ β-Thalassemia 
 
Evidences in research indicate that the availability of cure for the disorder is not evident and 
that the only recourse for individuals with this disorder is through frequent blood transfusion, 
iron chelation therapy as well as splenectomy if there is presence of an enlarged spleen 
(Cunningham et al, 2004). Marengo-Rowe (2007) argued that chronic cases of this disorder 
are treated with transfusions which take place on a monthly basis. However, this can 
eventually increase the iron deposition in the tissue all over the body, and cause progressive 
organ damage (Cohen, 1987). Cunningham et al (2004) further argued that the primary cause 
of mortality amongst patients with this disorder is due to an iron overload as most of the 
transfusion programmes are accompanied by treating with an iron chelating agent. Though 
Bonkovsky et al (2000) reported there are alternative therapies including the use of 
reactivation of HbF and transplantation of bone marrow, and it is important to accept that 
such a reactivation occurs only in some cases.  
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1.4 OCULAR IMPACT 
 
Abnormal growth of the bony orbit can cause limitation of ocular growth.  Therefore, ocular 
biometry and refractive in severe β-thalassemia individuals can be affected. Nowroozzadeh et 
al (2011) found a shorter axial length, thicker crystalline lens and steeper average 
keratometry in their subjects. Furthermore, posterior segment of the eyes can be affected as 
well. The abnormalities include degeneration of the RPE, retinal vascular abnormalities, and 
angioid streak (Gartaganis et al, 1989).  Jafari et al (2015) have reported the RPE 
degeneration was up to 17% in their study. The frequency of these abnormalities has been 
reported to increase with age (Gartaganis et al, 1989) and correlate with the number of blood 
transfusion (Jafari et al, 2015). According to Roy et al (2007), serious threats to vision are 
evident amongst patients who have thalassemia and sickle cell disorders. These patients are 
found to develop multi-focal areas of peripheral retinal neovascularisation. This can lead to 
vitreous haemorrhage.   
 
1.4.1 Ocular Iron Deposition 
 
Frequent blood transfusion can lead to iron deposition in all tissues in the body. The iron 
complexes can enter the RPE cells by binding to the surface transferrin receptors which are 
associated with the cytoskeleton (Hunt et al, 1989). When the excess iron complexes are 
transported into the cells, the hydroxyl radicals will be released through the Fenton reaction. 
These free radicals are harmful and toxic to the cells, as they can destroy the cell’s protein, 
lipid, DNA, as well as disrupt the blood retinal barrier. Tawara (1986) found that the ferritin 
particles were mainly accumulated in the Muller and RPE cells which can cause cell 
degeneration. However, Jeanny et al (2013) reported that deposition of excess iron was found 
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in the photoreceptor segments in their animal models. Some studies showed the macular iron 
level in the patients with AMD was significantly higher, and they believed that this play a 
role in pathogenesis of AMD (Blasiak et al, 2009; He et al, 2007). Roy et al (2007) further 
reported that ocular complications are evident in β-thalassemia as a result of frequent blood 
transfusions such as retinal toxicity from the overall iron accumulation. 
 
1.4.2 Effect of Iron Chelation Therapies 
 
Long-term iron chelation therapies can cause an unwanted adverse effect to the eyes. Jacobs 
(1977) showed that there are multiple ophthalmologic changes which can occur in patients 
who have been diagnosed with this disorder, ranging from impact on the retina (Gartaganis et 
al, 1989), optic nerve (Olivieri et al, 1986; Lakhanpal et al, 1984) and decrease in the overall 
visual acuity as a result of Deferoxamine used. Direct RPE cells toxicity to Deferoxamine has 
recently been reported by Klettner et al (2010). Taher et al (2006) have further argued that 
patients with oral Deferiprone have higher risk of RPE degeneration than those who took 
Deferoxamine. However, Jafari et al (2015) reported no significant difference between the 
iron chelating agents in causing the RPE degeneration.  
 
1.4.3 Optic Atrophy  
 
Multiple case studies have shown that optic atrophy is linked to HbE/ β-thalassemia disease. 
Sorcinelli et al (1999) presented a case of thalassemia intermedia with reducing of the space 
in the optic canal, which was caused by extra-medullary hematopoietic tissue expansion.  
This can lead to optic nerve compression and result in optic atrophy. Furthermore, this 
condition was found in related to the transfusion irregularity. Ittipunkul et al (2007) have 
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reported another case of bilateral progressive visual loss secondary to compressive optic 
neuropathy in a young β-thalassemia patient; in this case, they found that the extra-medullary 
haematopoietic tissue was originated from the adjacent paranasal sinuses. Recently, another 
case presentation by Pakdel et al (2011) reported that the causes of bilateral optic atrophy not 
only from the compression of the intracanal portion of the optic nerve but also from the 
compression of the optic chiasm in thalassemia intermedia. All of these studies indicate the 
possible impact of the extra-medullary haematopoietic tissue growth in thalassemia 
intermedia patients may lead to optic atrophy. 
 
1.4.4 Retinal Nerve Fibre Layer, Macular Thickness and Optic Nerve Head 
 
A tissue becomes hypoxic when there is lack of oxygen supply. It can even cause tissue 
damage or death including RNFL when the condition is prolonged or severe. OSAS is one of 
the medical problems that causing prolonged and recurrent hypoxia. Study has demonstrated 
the RNFL thickness was significantly thinner in OSAS patients although partly can be due to 
the relatively increase of IOP at night during sleep, when they lie in supine position (Perez-
Rico et al, 2014). Recent years Zengin et al (2014) have once again showed that the average 
RNFL thickness was significantly reduced in their 1 year study on OSAS patients. In β-
thalassemia, due to the abnormal haemoglobin, the oxygen being transported to all the tissue 
including retina and ONH is reduced and result in anemic hypoxia. In such conditions, the 
ONH may susceptible to glaucomatous damage even at normal intraocular pressure (Marcus 
et al, 2001).  
 
Furthermore, Changes in the thickness of RNFL and the macular can result from the 
abnormal RBCs. Study showed the RBCs in the β-thalassemia major individuals tend to 
9 
 
aggregate and form a large cluster of cell (Chen et al, 1996), and such changes will result in 
reducing of blood flow especially in the microcirculation. However, these aggregated RBCs 
size was found to become smaller after blood transfusion (Chen et al, 1996). Furthermore, β-
thalassemia patients frequently suffer from chronic hypercoagulable state with increased 
incidence of thromboembolic events (Taher et al, 2008). Factors that were found to be in 
association with hypercoagulable state includes deficiency of protein S and protein C 
(Shirahata et al, 1992), increased platelet aggregation (Winichagoon et al, 1981) and 
increased platelet counts after splenectomy (Eldor and Rachmilewitz, 2002). Individuals with 
infrequent blood transfusion tend to have more platelet counts and circulating damaged RBCs, 
which put them in a higher risk of thromboembolism events. Taher et al (2006) reported the 
thromboembolic events in splenectomized β-thalassemia intermedia patients are 4 times 
higher than β-thalassemia major. All these abnormal changes can reduce the blood flow and 
perfusion pressure to the eye, which would subsequently lead to ischemic changes.  
 
Few studies have shown significant thinning of the peripapillary RNFL thickness in some 
pathological anemia such as severe β-thalassemia and IDA (Aksoy et al, 2014; Turkyilmaz et 
al, 2013). However, there are no relevant data found in the literature that are related to the 
measurement of the macular thickness, RNFL and ONH parameters in HbE/ β-thalassemia.  
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1.5 OPTICAL COHERENCE TOMOGRAPHY   
 
Since OCT has been introduced in the year 1991 (Huang et al, 1991), it has become one of 
the most important diagnostic tools in ophthalmic practice for the past decade. It is a non-
invasive imaging technique that produces a cross-sectional image of the retina, RNFL and the 
ONH in high resolution quality. By using the concept of Michelson interferometer, OCT 
employs light from low-coherence source, which is directed into a fiber optic coupler and 
split into 2 beams; a reference beam and a sample beam. After the sample beam is 
backscattered from the retina, it interferes with the reference beam, and this produces an 
interference pattern (Fercher et al, 1988). This would enable it to detect the interface between 
different ocular tissues and retinal layers. According to the reflectivity changes between the 
different retinal layers, the RNFL thickness can be accurately measured (Huang et al, 1991; 
Sull et al, 2010). Other imaging techniques with different modalities such as CSLO and SLP 
are being used as well.  
 
1.5.1 Time Domain Optical Coherence Tomography 
 
The conventional TD-OCT was the first generation of OCT (Huang et al, 1991). TD-OCT 
was relatively time consuming when compare to the newer OCT, as this technology used a 
mobile reference arm mirror to measure the light echo time delay sequentially. Therefore, it 
reduced the precise retinal tissue mapping due to the eye movement during the procedure. 
Hee et al (1995) have demonstrated the used of TD-OCT on human retina tissue with a high 
axial resolution of approximately 10 μm. It produces 400 axial scan per second. 
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1.5.2 Spectral Domain Optical Coherence Tomography 
 
The OCT technology has evolved from the first generation TD-OCT to the second generation 
SD-OCT. SD-OCT used a broadband light source with approximately 830 nm together with a 
fixed reference arm mirror and a spectrometer, which significantly increase the scan speed to 
a new level of approximately 50,000 axial scan per second (Yaqoob et al, 2005). Other than 
this, SD-OCT also has a higher axial resolution of 5-7 μm (Wojtkowski et al, 2004; Ko et al, 
2005), produced fewer artefacts (Forte et al, 2009) and improved signal-to-noise ratio (de 
Boer et al, 2003) as compare to the TD-OCT. Nowadays, numbers of SD-OCT are 
manufactured by different companies such as Cirrus HD-OCT by Carl Zeiss Meditec, 3D-
OCT 1000 by Topcon Medical System, Spectralis OCT by Heidelberg Engineering GmbH, 
etc. 
 
Since its advent, various studies have been conducted looking at the macular thickness, 
RNFL and ONH parameters among the subjects of different age, gender, race and risk factors 
such as diabetes, and myopia (Faghihi et al, 2010; Song et al, 2010). Furthermore, some of 
the newer SD-OCT have even further increases the accuracy in ONH parameter measurement. 
This is due to the ability of detecting the BMO, a terminus of the bruch's membrane. BMO is 
an important landmark to define the optic disc margin as well as to delineate the ONH from 
the peripapillary tissue in the OCT (Strouthidis et al, 2009). Besides, BMO also act as an 
reliable reference point as its location does not significantly change even in a diseased eye 
such as glaucoma; and there was no association between the location of BMO and age 
(Belghith et al, 2016). Deeper tissue scanning such as choroid thickness measurement is 
possible with the use of SD-OCT (Manjunath et al, 2010; Regatieri et al, 2012). However, 
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these measurements can still be limited due to the presence of RPE layer which can cause 
scattering and reduce penetration of the light. 
 
Although the SD-OCT is far more superior to TD-OCT, the signal strength of an image is an 
important factor to decide the accuracy of a measurement. Cheung et al (2012) have 
demonstrated a significant difference in RNFL thickness between the images taken with 
signal strength of 10 and those with signal strength range from 5 to 7.  
 
1.5.3 Swept Source Optical Coherence Tomography 
 
SS-OCT is the third generation of OCT. In this latest technology, the narrowband swept laser 
source was chosen to produce a relatively longer wavelength, approximately 1050 nm. The 
longer wavelength gives the advantages on deeper tissue penetration including choroidal 
thickness measurement (Copete et al, 2014), less scattering of light, better axial resolution 
and more sensitive scan. Another plus point of SS-OCT is the  high speed tissue scanning 
which is more than 100,000 scans per second (Potsaid et al, 2010).  
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1.6 RESEARCH FOCUS  
 
Currently, there are very limited studies looking at the normative value of the ocular structure 
in β-thalassemia patients. This study will provide normative data of macular thickness, RNFL 
and ONH parameters in patients of HbE/ β-thalassemia which would serve as future reference 
and aid future researches. On the other hand, it may help to predict the changes of macular 
thickness, RNFL and ONH parameters in HbE/ β-thalassemia individuals. 
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STUDY OBJECTIVES 
 
2.1 GENERAL OBJECTIVE 
 
To evaluate the macular thickness, retinal nerve fiber layer (RNFL) thickness and optic nerve 
head (ONH) parameters in HbE/ beta thalassemia population. 
 
2.2 SPECIFIC OBJECTIVES 
 
2.2.1 To compare the mean macular thickness between the HbE/beta thalassemia and 
control. 
 
2.2.2 To compare the mean RNFL thickness between the HbE/beta thalassemia and 
control. 
 
2.2.3 To compare the ONH parameters between the HbE/beta thalassemia and 
control. 
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3.1 STUDY DESIGN 
 
Cross sectional study. 
 
3.2 STUDY POPULATION, SETTING AND PERIOD 
 
The study was conducted from June 2014 until March 2016. Sixty-six HbE / β-Thalassemia 
patients, who were eligible, based on the selection criteria, were recruited from 3 centres; 
Ophthalmology Clinic in Hospital Sultanah Aminah (HSA), Hospital Raja Perempuan Zainab 
II (HRPZ II) and Hospital University Sains Malaysia (HUSM). The HbE/ β-Thalassemia 
patients and control subjects were matched according to age and gender. 
 
3.3 SAMPLING AND SAMPLE SIZE 
 
3.3.1 Sampling method 
 
All patients who attended the Ophthalmology Clinic HSA, HRPZ II and HUSM 
between June 2014 and March 2016 and eligible based on the selection criteria, were 
included in the study. Convenience sampling was used for the HbE/ β-Thalassemia 
group. These patients were selected during their follow up in the Hematology Clinic. 
Simple random sampling was used for the control group which is from normal 
population. 
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3.3.2 Sample size 
 
Sample size was calculated using Power and Sample Size Calculation (PS) Software 
version 3.0.10 using t-test formula.  
 
3.3.2.1 Objective 1 
 
To compare the macular thickness between HbE/ β-Thalassemia and the normal 
population. 
 
• Mean macular thickness in HbE/ β-Thalassemia: no published data. 
• Mean macular thickness in normal population: 275.66 ± 14.12um  
(Song et al, 2010). 
• Sample: independent. 
• Input: α= 0.05, power =0.8, δ =9, σ = 14.12, m=1. 
• Sample size: 40 
• By the addition of 20% drop outs, the sample size that needs to be 
collected for each group is 48 subjects. 
 
3.3.2.2 Objective 2 
 
To compare the retinal nerve fiber layer (RNFL) thickness between HbE/ β-
Thalassemia and the normal population. 
 
• Mean RNFL in HbE/ β-Thalassemia: no published data. 
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• Mean RNFL in normal population.: 98.7 ± 10.9um (Seibold et al, 
2010) 
• Sample: independent. 
• Input: α= 0.05, power =0.8, δ =6.0, σ = 10.9, m=1. 
• Sample size: 53. 
• By the addition of 20% drop outs, the sample size that needs to be 
collected for each group is 65 subjects. 
 
3.3.2.3 Objective 3 
 
To compare the optic nerve head (ONH) parameters between HbE/ β-Thalassemia and 
the normal population. 
 
(i) To compare the mean disc area between HbE/ β-Thalassemia and the normal 
population. 
 
• Mean optic disc area in HbE/ β-Thalassemia: no published data. 
• Mean optic disc area in normal population: 1.98 ± 0.50 square 
millimetres (Resch et al, 2012). 
• Sample: independent. 
• Input: α= 0.05, power =0.8, δ =0.28, σ = 0.50, m=1. 
• Sample size: 51. 
• By the addition of 20% drop outs, the sample size that needs to be 
collected for each group is 60 subjects. 
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(ii) To compare the mean rim area (RA) between HbE/ β-Thalassemia and the 
normal population. 
 
• Mean rim area in HbE/ β-Thalassemia: no published data. 
• Mean rim area in normal population: 1.56 ± 0.49 square millimetres 
(Resch et al, 2012). 
• Sample: independent. 
• Input: α= 0.05, power =0.8, δ =0.28, σ = 0.49, m=1. 
• Sample size: 49. 
• By the addition of 20% drop outs, the sample size that needs to be 
collected for each group is 60 subjects. 
 
(iii) To compare the mean cup volume (CV) between HbE/ β-Thalassemia and the 
normal population. 
 
• Mean cup volume in HbE/ β-Thalassemia: no published data. 
• Mean cup volume in normal population: 0.099 ± 0.11 cubic 
millimetres (Resch et al, 2012). 
• Sample: independent. 
• Input: α= 0.05, power =0.8, δ =0.06, σ = 0.11, m=1. 
• Sample size: 54. 
• By the addition of 20% drop outs, the sample size that needs to be 
collected for each group is 66 subjects. 
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(iv) To compare the mean average cup disc ratio (ACDR) between HbE/ β-
Thalassemia and the normal population. 
 
• Mean average cup disc ratio (ACDR) in HbE/ β-Thalassemia: no 
published data. 
• Mean average cup disc ratio (ACDR) in normal population: 0.36 ± 
0.17 (Resch et al, 2012). 
• Sample: independent. 
• Input: α= 0.05, power =0.8, δ =0.10, σ = 0.17, m=1. 
• Sample size: 46. 
• By the addition of 20% drop outs, the sample size that needs to be 
collected for each group is 56 subjects. 
 
(v) To compare the mean vertical cup disc ratio (VCDR) between HbE/ β-
Thalassemia and the normal population. 
 
• Mean vertical cup disc ratio (VCDR) in HbE/ β-Thalassemia: no 
published data. 
• Mean vertical cup disc ratio (VCDR) in normal population: 0.68 ± 
0.14 (Moghimi et al, 2012). 
• Sample: independent. 
• Input: α= 0.05, power =0.8, δ =0.2, σ = 0.14, m=1. 
• Sample size: 33. 
• By the addition of 20% drop outs, the sample size that needs to be 
collected for each group is 40 subjects. 
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Based on objective 1, objective 2 and objective 3, the biggest sample size chosen for 
this study is 66 subjects for each group. 
 
3.4 SELECTION CRITERIA 
 
3.4.1 HbE/ β-Thalassemia Subjects 
 
3.4.1.1 Inclusion criteria: 
 
(i) Patients have been diagnosed with HbE/ β-Thalassemia and 
already in the National Thalassemia database. 
 
3.4.1.2 Exclusion criteria: 
 
(i) Previous ocular surgery and trauma. 
(ii) Premorbid ocular pathology such as glaucoma, ocular 
hypertension, any macular or retinal pathology, any optic nerve 
pathology. 
(iii) Myopia more than -3.00D. 
(iv) Systemic co-morbidities such as diabetes mellitus, 
hypertension, and ischemic heart disease. 
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3.4.2 Control Subjects 
 
3.4.2.1 Inclusion criteria: 
 
(i) Healthy individuals. 
(ii) Age matched. 
 
3.4.2.2 Exclusion criteria 
 
(i) Previous ocular surgery and trauma. 
(ii) Premorbid ocular pathology such as glaucoma, ocular 
hypertension, any macular or retinal pathology, any optic nerve 
pathology. 
(iii) Myopia more than -3.00D. 
(iv) Systemic co-morbidities such as diabetes mellitus, 
hypertension, and ischemic heart disease. 
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